

## IPO Expected Timetable#

| Stock Code | Stock Name | Application lists close | Allotment Date | Listing Date |
|------------|------------|-------------------------|----------------|--------------|
| 02170      | BASECARE-B | 2021/02/01              | 2021/02/05     | 2021/02/08   |

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit [www.cfs.com.hk](http://www.cfs.com.hk) or contact our account executives or customer service officers

## Subscription Details via CASH Securities

|                                     |                       |
|-------------------------------------|-----------------------|
| Offer Period                        | 2021/01/27-2021/02/01 |
| Closing Time for Margin Application | N/A                   |
| Subscription Fee                    | N/A                   |
| Indicative Interest Rate            | N/A                   |
| Days For Margin Financing           | N/A                   |

\*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.  
\*\* Eligible new and existing customers who successfully activate the electronic direct debit authorization (DDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.

## Suzhou Basecare Medical Corporation Limited (2170.HK)

### Share Offer Highlights

|                                  |   |
|----------------------------------|---|
| Total Number of Offer Shares:    | 66,667,000 H Shares (subject to the Over-allotment Option)                |
| - Number of Public Offer Shares: | 6,667,000 H Shares (subject to adjustment)                                |
| - Number of Placing Shares:      | 60,000,000 H Shares (subject to adjustment and the Over-allotment Option) |
| Number of Shares per Lot:        | 500 Shares  |
| Offer Price:                     | HKD 26.36 - 27.36 per Share   |
| 2019 Historical P/E ratio:       | -   |
| Sponsor:                         | Citic Securities  |

### Company Overview

The Company is an innovative platform of genetic testing solutions for assisted reproduction in China, according to Frost & Sullivan. Its PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in in vitro fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA, compare to other PGT-A products based on fluorescence in situ hybridization (FISH) and quantitative polymerase chain reaction (qPCR) technologies. The NMPA registration of its PGT-A kit, in February 2020, as a Class III "innovative medical device," marked the birth of a regulated third-generation IVF market in China in which it is, to date, the only approved kit maker.

For the year ended December 31, 2018 and 2019 and the nine months ended September 30, 2020, the Company's net losses were RMB154.88 mn, RMB531.34 mn and RMB851.38 mn respectively.

### Source

IPO Prospectus

### Contact Us

|                        |  |                    |
|------------------------|--|--------------------|
| Headquarters:          | 22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong  | (852) 2287 8788    |
| HK Services Centre:    | 6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon   | (852) 2748 0110    |
| China Services Centre: | 1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen                                   | (86-755) 2216 5888 |
|                        | 2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai | (86-21) 3227 9888  |
|                        | Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou                | (020) 8981 7463    |
|                        | Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan                                   | (86-769) 2223 0026 |



**Declaration:**

The above information is provided and distributed by CASH Financial Services Group Limited ( "CASH" ). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.